Timeframe
Operating costs
Operating costs – (Table representation)
SEC report release date | Cost of sales | Research and development | Marketing, selling, and administrative | Acquired in-process research and development | Asset impairment, restructuring, and other special charges | Other (income) expense |
|---|---|---|---|---|---|---|
SEC report date:30 Apr. 26 | Cost of sales: 3,577,000,000 $ | Research and development: 3,510,000,000 $ | Marketing, selling, and administrative: 2,934,000,000 $ | Acquired in-process research and development: 584,000,000 $ | Asset impairment, restructuring, and other special charges: 279,000,000 $ | Other (income) expense: 65,000,000 $ |
SEC report date:12 Feb. 26 | Cost of sales: 3,371,700,000 $ | Research and development: 3,801,500,000 $ | Marketing, selling, and administrative: 3,131,500,000 $ | Acquired in-process research and development: 528,800,000 $ | Asset impairment, restructuring, and other special charges: 84,100,000 $ | Other (income) expense: 108,300,000 $ |
SEC report date:30 Oct. 25 | Cost of sales: 3,008,300,000 $ | Research and development: 3,465,700,000 $ | Marketing, selling, and administrative: 2,740,700,000 $ | Acquired in-process research and development: 655,700,000 $ | Asset impairment, restructuring, and other special charges: 364,900,000 $ | Other (income) expense: 133,100,000 $ |
SEC report date:07 Aug. 25 | Cost of sales: 2,447,800,000 $ | Research and development: 3,336,100,000 $ | Marketing, selling, and administrative: 2,753,000,000 $ | Acquired in-process research and development: 153,800,000 $ | Asset impairment, restructuring, and other special charges: – | Other (income) expense: 90,600,000 $ |
SEC report date:01 May. 25 | Cost of sales: 2,224,200,000 $ | Research and development: 2,733,700,000 $ | Marketing, selling, and administrative: 2,468,800,000 $ | Acquired in-process research and development: 1,571,700,000 $ | Asset impairment, restructuring, and other special charges: 35,000,000 $ | Other (income) expense: 239,000,000 $ |
SEC report date:19 Feb. 25 | Cost of sales: 2,403,800,000 $ | Research and development: 3,022,500,000 $ | Marketing, selling, and administrative: 2,424,500,000 $ | Acquired in-process research and development: 189,200,000 $ | Asset impairment, restructuring, and other special charges: 344,000,000 $ | Other (income) expense: 110,100,000 $ |
SEC report date:30 Oct. 24 | Cost of sales: 2,170,800,000 $ | Research and development: 2,734,100,000 $ | Marketing, selling, and administrative: 2,099,800,000 $ | Acquired in-process research and development: 2,826,400,000 $ | Asset impairment, restructuring, and other special charges: 81,600,000 $ | Other (income) expense: -62,000,000 $ |
SEC report date:08 Aug. 24 | Cost of sales: 2,170,200,000 $ | Research and development: 2,711,200,000 $ | Marketing, selling, and administrative: 2,117,300,000 $ | Acquired in-process research and development: 154,300,000 $ | Asset impairment, restructuring, and other special charges: 435,000,000 $ | Other (income) expense: 197,600,000 $ |
SEC report date:30 Apr. 24 | Cost of sales: 1,673,500,000 $ | Research and development: 2,522,800,000 $ | Marketing, selling, and administrative: 1,952,200,000 $ | Acquired in-process research and development: 110,500,000 $ | Asset impairment, restructuring, and other special charges: – | Other (income) expense: -27,100,000 $ |
SEC report date:21 Feb. 24 | Cost of sales: 1,788,000,000 $ | Research and development: 2,562,700,000 $ | Marketing, selling, and administrative: 1,924,600,000 $ | Acquired in-process research and development: 622,600,000 $ | Asset impairment, restructuring, and other special charges: 67,700,000 $ | Other (income) expense: -121,000,000 $ |
SEC report date:02 Nov. 23 | Cost of sales: 1,860,100,000 $ | Research and development: 2,409,100,000 $ | Marketing, selling, and administrative: 1,803,900,000 $ | Acquired in-process research and development: 2,975,100,000 $ | Asset impairment, restructuring, and other special charges: – | Other (income) expense: 23,200,000 $ |
SEC report date:08 Aug. 23 | Cost of sales: 1,807,400,000 $ | Research and development: 2,356,500,000 $ | Marketing, selling, and administrative: 1,925,400,000 $ | Acquired in-process research and development: 97,100,000 $ | Asset impairment, restructuring, and other special charges: – | Other (income) expense: 36,800,000 $ |
SEC report date:27 Apr. 23 | Cost of sales: 1,626,700,000 $ | Research and development: 1,985,100,000 $ | Marketing, selling, and administrative: 1,749,200,000 $ | Acquired in-process research and development: 105,000,000 $ | Asset impairment, restructuring, and other special charges: – | Other (income) expense: -35,700,000 $ |
Expand table